A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection - PubMed (original) (raw)
Comparative Study
. 2001 Jul 15;93(2):243-51.
doi: 10.1002/ijc.1323.
Affiliations
- PMID: 11410873
- DOI: 10.1002/ijc.1323
Comparative Study
A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection
H Jonuleit et al. Int J Cancer. 2001.
Abstract
Dendritic cells (DCs) elicit potent anti-tumoral T-cell responses in vitro and in vivo. However, different types of DC have yet to be compared for their capacity to induce anti-tumor responses in vivo at different developmental stages. Herein, we correlated the efficiencies of different types of monocyte-derived DC as vaccines on the resulting anti-tumor immune responses in vivo. Immature and mature DCs were separately pulsed with a peptide derived from tyrosinase, MelanA/MART-1 or MAGE-1 and a recall antigen. Both DC populations were injected every 2 weeks in different lymph nodes of the same patient. Immune responses were monitored before, during and after vaccination. Mature DCs induced increased recall antigen-specific CD4(+) T-cell responses in 7/8 patients, while immature DCs did so in only 3/8. Expansion of peptide-specific IFN-gamma-producing CD8(+) T cells was observed in 5/7 patients vaccinated with mature DCs but in only 1/7 using immature DCs. However, these functional data did not correlate with the tetramer staining. Herein, immature DCs also showed expansion of peptide-specific T cells. In 2/4 patients vaccinated with mature DCs, we observed induction of peptide-specific cytotoxic T cells, as monitored by chromium-release assays, whereas immature DCs failed to induce peptide-specific cytotoxic T cells in the same patients. Instead, FCS-cultured immature DCs induced FCS-specific IgE responses in 1 patient. Our data demonstrate that this novel vaccination protocol is an efficient approach to compare different immunization strategies within the same patient. Thus, our data define FCS-free cultured mature DCs as superior inducers of T-cell responses in melanoma patients.
Copyright 2001 Wiley-Liss, Inc.
Similar articles
- Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ. de Vries IJ, et al. Clin Cancer Res. 2003 Nov 1;9(14):5091-100. Clin Cancer Res. 2003. PMID: 14613986 - Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients.
Tuettenberg A, Becker C, Huter E, Knop J, Enk AH, Jonuleit H. Tuettenberg A, et al. Int J Cancer. 2006 May 15;118(10):2617-27. doi: 10.1002/ijc.21679. Int J Cancer. 2006. PMID: 16353138 Clinical Trial. - Optimizing the exogenous antigen loading of monocyte-derived dendritic cells.
Dieckmann D, Schultz ES, Ring B, Chames P, Held G, Hoogenboom HR, Schuler G. Dieckmann D, et al. Int Immunol. 2005 May;17(5):621-35. doi: 10.1093/intimm/dxh243. Epub 2005 Apr 11. Int Immunol. 2005. PMID: 15824067 Retracted. - Dendritic cell gene therapy.
Onaitis M, Kalady MF, Pruitt S, Tyler DS. Onaitis M, et al. Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. doi: 10.1016/s1055-3207(02)00027-3. Surg Oncol Clin N Am. 2002. PMID: 12487060 Review. - Processing and presentation of antigens by dendritic cells: implications for vaccines.
Bhardwaj N. Bhardwaj N. Trends Mol Med. 2001 Sep;7(9):388-94. doi: 10.1016/s1471-4914(01)02101-3. Trends Mol Med. 2001. PMID: 11530333 Review.
Cited by
- A pseudotyped adenovirus serotype 5 vector with serotype 49 fiber knob is an effective vector for vaccine and gene therapy applications.
Bliss CM, Hulin-Curtis SL, Williams M, Marušková M, Davies JA, Statkute E, Baker AT, Stack L, Kerstetter L, Kerr-Jones LE, Milward KF, Russell G, George SJ, Badder LM, Stanton RJ, Coughlan L, Humphreys IR, Parker AL. Bliss CM, et al. Mol Ther Methods Clin Dev. 2024 Jul 30;32(3):101308. doi: 10.1016/j.omtm.2024.101308. eCollection 2024 Sep 12. Mol Ther Methods Clin Dev. 2024. PMID: 39206304 Free PMC article. - Lymph node targeting for immunotherapy.
Wang Y, Wang H. Wang Y, et al. Immunooncol Technol. 2023 Jun 28;20:100395. doi: 10.1016/j.iotech.2023.100395. eCollection 2023 Dec. Immunooncol Technol. 2023. PMID: 37719676 Free PMC article. Review. - Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis.
Carpenter EL, Van Decar S, Adams AM, O'Shea AE, McCarthy P, Chick RC, Clifton GT, Vreeland T, Valdera FA, Tiwari A, Hale D, Kemp Bohan P, Hickerson A, Smolinsky T, Thomas K, Cindass J, Hyngstrom J, Berger AC, Jakub J, Sussman JJ, Shaheen MF, Yu X, Wagner TE, Faries M, Peoples GE. Carpenter EL, et al. J Immunother Cancer. 2023 Aug;11(8):e006665. doi: 10.1136/jitc-2023-006665. J Immunother Cancer. 2023. PMID: 37536936 Free PMC article. Clinical Trial. - Biomaterials Facilitating Dendritic Cell-Mediated Cancer Immunotherapy.
Dong H, Li Q, Zhang Y, Ding M, Teng Z, Mou Y. Dong H, et al. Adv Sci (Weinh). 2023 Jun;10(18):e2301339. doi: 10.1002/advs.202301339. Epub 2023 Apr 23. Adv Sci (Weinh). 2023. PMID: 37088780 Free PMC article. Review. - Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients.
Bloemendal M, Bol KF, Boudewijns S, Gorris MAJ, de Wilt JHW, Croockewit SAJ, van Rossum MM, de Goede AL, Petry K, Koornstra RHT, Figdor C, Gerritsen WR, Schreibelt G, de Vries IJM. Bloemendal M, et al. Oncoimmunology. 2021 Dec 30;11(1):2015113. doi: 10.1080/2162402X.2021.2015113. eCollection 2022. Oncoimmunology. 2021. PMID: 36524210 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials